Bristol Advisors LLC purchased a new position in shares of AbbVie Inc (NYSE:ABBV) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,900 shares of the company’s stock, valued at approximately $369,000. AbbVie accounts for approximately 0.6% of Bristol Advisors LLC’s investment portfolio, making the stock its 25th largest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Morgan Stanley raised its stake in shares of AbbVie by 3.2% in the second quarter. Morgan Stanley now owns 11,134,470 shares of the company’s stock valued at $1,031,608,000 after acquiring an additional 348,882 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of AbbVie by 15.9% in the second quarter. Janus Henderson Group PLC now owns 5,243,956 shares of the company’s stock valued at $485,867,000 after acquiring an additional 717,452 shares during the last quarter. Bank of Montreal Can raised its stake in shares of AbbVie by 9.2% in the third quarter. Bank of Montreal Can now owns 5,210,247 shares of the company’s stock valued at $492,786,000 after acquiring an additional 438,201 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AbbVie by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 4,824,617 shares of the company’s stock valued at $447,001,000 after acquiring an additional 157,594 shares during the last quarter. Finally, Aristotle Capital Management LLC raised its stake in shares of AbbVie by 0.9% in the first quarter. Aristotle Capital Management LLC now owns 3,787,873 shares of the company’s stock valued at $358,522,000 after acquiring an additional 34,727 shares during the last quarter. Hedge funds and other institutional investors own 69.47% of the company’s stock.

Shares of AbbVie stock opened at $91.53 on Monday. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.20 and a quick ratio of 1.08. The company has a market capitalization of $137.68 billion, a P/E ratio of 16.34, a P/E/G ratio of 0.85 and a beta of 1.62. AbbVie Inc has a fifty-two week low of $77.50 and a fifty-two week high of $125.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.13. The business had revenue of $8.24 billion during the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a net margin of 23.50% and a return on equity of 2,006.63%. AbbVie’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.41 earnings per share. Equities analysts predict that AbbVie Inc will post 7.93 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be issued a $1.07 dividend. The ex-dividend date is Monday, January 14th. This represents a $4.28 dividend on an annualized basis and a dividend yield of 4.68%. This is a positive change from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s dividend payout ratio (DPR) is currently 68.57%.

A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of AbbVie from a “sell” rating to a “hold” rating in a research note on Monday, November 12th. Argus cut their target price on shares of AbbVie from $130.00 to $115.00 and set a “buy” rating for the company in a research note on Tuesday, November 6th. BMO Capital Markets cut their target price on shares of AbbVie from $78.00 to $71.00 and set an “underperform” rating for the company in a research note on Monday, November 5th. Barclays reiterated a “hold” rating and issued a $90.00 target price on shares of AbbVie in a research note on Sunday, November 4th. Finally, Credit Suisse Group set a $85.00 target price on shares of AbbVie and gave the company a “hold” rating in a research note on Friday, November 2nd. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $103.68.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/19/bristol-advisors-llc-invests-369000-in-abbvie-inc-abbv.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

Featured Story: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.